Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

NCT03012230 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Neoplasm in the Bone
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab
DRUG: Ruxolitinib Phosphate

Sponsor

Mayo Clinic